Portal de investigação
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Dados básicos
- Código:
- Estudo Clínico Académico
- Protocolo:
- Estudo Clínico Académico
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2021
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes
Review. 10.1177/17562848221142673. 2022
A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn's disease prognosis - a prospective study
Meeting Abstract. 2023
Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelines
Meeting Abstract. 10.1093/ecco-jcc/jjae040. 2024
Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort Study
Abreu, C; (...); Magro, F
Article. 10.3390/vaccines11030703. 2023
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
Article. 10.1111/eci.14283. 2024
Angiotensin-converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis
Article. 10.1111/jgh.16541. 2024
Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations
Meeting Abstract. 2023
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
Article. 10.1093/ibd/izac061. 2023
Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review
Review. 10.3390/ijms252312852. 2024
Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease
Meeting Abstract. 2022
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
Meeting Abstract. 10.1136/gutjnl-2022-BSG.74. 2022
Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''
Editorial Material. 10.1016/j.dld.2023.12.006. 2024
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study
Article. 10.1093/ibd/izae162. 2024
Benefit-risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study
Meeting Abstract. 2024
Bile salts and proinflammatory cytokines inhibit MCT1-mediated cellular uptake of butyrate and interfere with its antiproliferative properties
Couto, MR; (...); Martel, F.
Article. 10.1016/j.yexcr.2023.113670. 2023
Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal
Article. 10.1159/000525206. 2023
CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
Meeting Abstract. 2022
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
Article. 10.1111/apt.17751. 2024
Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine
Editorial Material. 10.20344/amp.21371. 2024
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study
Article. 10.1002/ueg2.12492. 2024
Composite outcomes in Crohn's disease: a systematic review and meta-analysis of observational studies
Meeting Abstract. 2022
Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis
Magro, F; (...); Moreira, PL
Review. 10.1177/17562848221092754. 2022
Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis
Magro, F; (...); Moreira, P
Review. 10.1002/ueg2.12183. 2022
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
Ma, C; (...); Jairath, V
Article. 10.1053/j.gastro.2022.06.068. 2022
COVID-19 Vaccines in IBD Patients: Particularities and Future Perspectives
Editorial Material. 10.1093/ecco-jcc/jjac042. 2022
Changing paradigms in management of inflammatory bowel disease
Editorial Material. 10.1002/ueg2.12347. 2022
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations
Schreiber, S; (...); Peyrin-Biroulet, L
Article. 10.1093/ecco-jcc/jjad130. 2023
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Review. 10.1002/ueg2.12671. 2024
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
Caron, B; (...); Peyrin-Biroulet, L
Review. 10.1002/ueg2.12283. 2022
Definitions of Histological Abnormalities in Inflammatory Bowel Disease: an ECCO Position Paper
Feakins, R; (...); Rosini, F
Article. 10.1093/ecco-jcc/jjad142. 2023
Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper
Meeting Abstract. 2024
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis
Article. 10.1093/ibd/izae204. 2024
Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
Peyrin-Biroulet, L; (...); Kubassova, O
Meeting Abstract. 2023
DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES
Meeting Abstract. 2023
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey
Parigi, TL; (...); Danese, S
Letter. 10.1016/S2468-1253(22)00085-1. 2022
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Parigi, TL; (...); Danese, S
Review. 10.1016/S2468-1253(23)00154-1. 2023
Dipeptidyl peptidase 4 (DPP4) in fecal samples: validation of the extraction methodology and stability in short-term storage conditions
Gomes, SF; (...); Magro, F
Article. 10.1515/cclm-2023-0139. 2023
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus
D'Amico, F; (...); Danese, S
Review. 10.1093/ibd/izad159. 2023
Drug Prescribing Analysis: The Burden Of Orphan Drugs In A Tertiary Hospital Budget
Meeting Abstract. 2023
Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials
Meeting Abstract. 2023
EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Meeting Abstract. 2023
EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL OUTCOMES WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Meeting Abstract. 2024
ECCO Governing Board European Crohn's and Colitis Organisation - ECCO, Ungargasse 6/13, A-1030 Vienna, Austria
Letter. 10.1093/ecco-jcc/jjab225. 2022
ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology
Magro, F; (...); Feakins, R
Article. 10.1093/ecco-jcc/jjac006. 2022
Editorial: elderly onset inflammatory bowel disease --clues from the largest population--based cohort study
Estevinho, MM, Magro, F
Editorial Material. 10.1111/apt.17543. 2023
Effect of Toll-like receptor-2, -4, -5, -7, and NOD2stimulation on potassium channel conductance in intestinal epithelial cells (vol 323, pg G410, 2022)
Cosme, D., Soares-da-Silva, P., Magro, F.
Correction. 10.1152/ajpgi.00139.2023_COR. 2023
Effect of Toll-like receptor-2,-4,-5,-7, and NOD2 stimulation on potassium channel conductance in intestinal epithelial cells
Cosme, Dina, Soares-da-Silva, Patricio, Magro, Fernando
Article. 10.1152/ajpgi.00139.2022. 2022
EFFECT OF UPADACITINIB ON INFLAMMATORY MARKERS AND CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE IN THE PHASE 3, U-EXCEL, U-EXCEED, AND U-ENDURE STUDIES
Meeting Abstract. 2023
Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
Meeting Abstract. 2023
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
Article. 10.1016/j.cgh.2023.11.010. 2024
Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trials
Meeting Abstract. 2024
Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension
Meeting Abstract. 2024
Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial
Peyrin-Biroulet, L; (...); Danese, S
Meeting Abstract. 2022
EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN'S DISEASE: RESULTS FROM THE STARDUST TRIAL
Meeting Abstract. 2022
Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn's Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Loftus, E; (...); Lichtenstein, G
Meeting Abstract. 10.14309/01.ajg.0000995764.89379.2a. 2023
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
Guillo, L; (...); Peyrin-Biroulet, L
Review. 10.1016/S2468-1253(21)00297-1. 2022
Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis
Letter. 10.1016/j.cgh.2021.08.003. 2022
Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue
De Sousa, HT, Gullo, I, Magro, FERNANDO
Letter. 10.1016/j.cgh.2022.06.023. 2023
Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease
Meeting Abstract. 2024
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis
Magro, F; (...); Santiago, M
Review. 10.1002/ueg2.12366. 2023
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Review. 10.1080/17474124.2024.2326838. 2024
Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn's Disease
Meeting Abstract. 2022
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Magro, F.; (...); Carneiro, F.
Article. 10.1016/j.cgh.2020.09.017. 2021
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study
Magro, F; (...); Dias, CC
Article. 10.1002/ueg2.12420. 2023
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Peyrin-Biroulet, L; (...); Beaugerie, L
Article. 10.1016/j.cgh.2022.09.018. 2023
Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis
Review. 10.1093/ibd/izac203. 2023
Impact of mirikizumab on histologic measures of intestinal inflammation in a phase 2 study of patients with moderate-severe crohn's disease
Meeting Abstract. 10.1136/gutjnl-2023-BSG.370. 2023
Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn's Disease
Meeting Abstract. 2021
Impact of mirikizumab therapy on histological measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
Meeting Abstract. 2022
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Review. 10.1016/j.autrev.2023.103504. 2024
Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?
Santiago, M; (...); Magro, F
Article. 10.14309/ctg.0000000000000481. 2022
Inflammation of the appendix in ulcerative colitis - Does it have a predictive value?
Magro, F, Estevinho, MM, Feakins, R
Editorial Material. 10.1002/ueg2.12181. 2021
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
Caron, B; (...); Peyrin-Biroulet, L
Review. 10.3390/medicina59010183. 2023
Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 a) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis
Article. 10.3390/biomedicines11123137. 2023
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
Caron, B; (...); Peyrin-Biroulet, L
Article. 10.1016/j.cgh.2022.02.032. 2022
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
Review. 10.3390/jcm12031142. 2023
Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results
Meeting Abstract. 2024
Long-term effect of Toll-like receptor-2,-4,-5,-7 and NOD2 stimulation on Na plus , K plus -ATPase activity and expression in intestinal epithelial cells
Cosme, D, soares-da-silva, p, Magro, F
Article. 10.1152/ajpcell.00208.2022. 2023
Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?
Article. 10.1093/jcag/gwad034. 2023
Microbiota therapeutics for inflammatory bowel disease: the way forward
Article. 10.1016/S2468-1253(23)00441-7. 2024
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
Louis, E; (...); Travis, SP
Article. 10.1136/bmjgast-2021-000853. 2022
Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib
Meeting Abstract. 2024
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Article. 10.1080/00365521.2021.2015801. 2022
Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients
Fernandes, BM; (...); Bernardes, J.
Article. 2022
Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients
Article. 2022
Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
Editorial Material. 10.1093/ecco-jcc/jjae136. 2024
Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
Review. 10.1111/apt.18315. 2024
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Olivera, PA; (...); Peyrin-Biroulet, L
Review. 10.1093/ecco-jcc/jjac133. 2023
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Schreiber, S; (...); Reinisch, W
Review. 10.1007/s12325-021-01990-6. 2022
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Jan, 10.1007/s12325-021-01990-6, 2022)
Schreiber, S; (...); Reinisch, W
Correction. 10.1007/s12325-022-02082-9. 2022
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
Imbrizi, M, Magro, F, Coy, CSR
Review. 10.3390/ph16091272. 2023
Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
Martins, A; (...); de Abreu, CMF
Meeting Abstract. 2023
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
D'Amico, F; (...); Danese, S
Review. 10.1093/ecco-jcc/jjab206. 2022
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
D'Amico, F; (...); Danese, S
Article. 10.3390/jcm12196350. 2023
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
Review. 10.1080/17474124.2024.2397650. 2024
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus
Article. 10.1093/ecco-jcc/jjae026. 2024
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD international consensus
Meeting Abstract. 2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Article. 10.1016/j.dld.2024.03.010. 2024
Proactive Infliximab monitoring improves the rates of transmural remission in Crohn's disease - a propensity score matched analysis
Meeting Abstract. 2024
Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis
Fernandes, SR; (...); Magro, F
Article. 10.1093/ibd/izad272. 2023
Proportion of IBD patients with suboptimal control in daily clinical practice - real-world evidence from the IBD Podcast study
Meeting Abstract. 2024
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study
Article. 10.1002/ueg2.12572. 2024
Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
Review. 10.1177/17562848231155987. 2023
Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
Magro, F, Estevinho, MM
Editorial Material. 10.1002/ueg2.12432. 2023
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
Magro, F; (...); Peyrin-Biroulet, L
Article. 10.1093/ecco-jcc/jjad050. 2023
Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial
Meeting Abstract. 2024
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
Magro, F; (...); Dias, CC
Article. 10.1016/j.cgh.2021.12.004. 2022
SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS
Meeting Abstract. 2022
The degree of bowel remission predicts phenotype progression in Crohn's disease
Article. 10.1002/ueg2.12581. 2024
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Article. 10.5217/ir.2022.00006. 2022
The importance of a Clinical Pharmacology Unit to a Pharmacy and Therapeutics Committee, in a tertiary hospital
Meeting Abstract. 2023
The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients
Meeting Abstract. 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
Article. 10.1093/ecco-jcc/jjae014. 2024
The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review
Santiago, M; (...); Magro, F
Review. 10.1093/ibd/izab334. 2022
The Process of Developing a Disease Activity Index in Microscopic Colitis
Article. 10.1093/ecco-jcc/jjab170. 2022
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab
Article. 10.1016/j.dld.2023.10.027. 2024
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease
Sousa, P; (...); Magro, F
Article. 10.1016/j.dld.2021.05.038. 2021
Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease
Fernandes, SR; (...); Magro, F
Article. 10.1002/ueg2.12497. 2023
Transmural Remission Associates with a Lower Risk of Phenotype Progression in Crohn's Disease
Meeting Abstract. 2024
Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
Article. 10.1002/ueg2.12356. 2023
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
Danese, S; (...); Peyrin-Biroulet, L
Article. 10.1016/S2468-1253(21)00474-X. 2022
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study
Article. 10.1002/ueg2.12288. 2022
Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results
Meeting Abstract. 2024
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial
Panés, J; (...); Dignass, A
Article. 10.1002/ueg2.12384. 2023
Vaccines - beliefs and concerns: the voice of patients with inflammatory immunomediated diseases
Abreu, C; (...); Magro, F
Article. 10.1097/MEG.0000000000002589. 2023
Viable Mycobacterium avium subsp. paratuberculosis Colonizes Peripheral Blood of Inflammatory Bowel Disease Patients
Estevinho, MM; (...); Sarmento, A
Article. 10.3390/microorganisms11061520. 2023
